I presume investors here are aware of this trial:
Alzheimers Dement. 2014 Oct;10(5 Suppl):S364-73. doi: 10.1016/j.jalz.2013.09.010. Epub 2014 Jan 10.
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.
Marek GJ1, Katz DA2, Meier A2, Greco N 4th2, Zhang W2, Liu W2, Lenz RA2.
Author information
Abstract
BACKGROUND:
In this study we assessed increased cortisol in Alzheimer's disease (AD) patients. The selective 11-β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor ABT-384 blocked regeneration of active cortisol and this tests the hypothesis that intracellular hypercortisolism contributes to cognitive impairment.
METHODS:
In this double-blind, placebo- and active-controlled phase II study we examine the efficacy and safety of ABT-384 given 10 mg or 50 mg once daily, donepezil 10 mg once daily, or placebo for 12 weeks in subjects with mild-to-moderate AD. The primary efficacy end point was the change from baseline to final evaluation on the 13-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) total score.
RESULTS:
The study was terminated for futility after randomization of 267 subjects. ABT-384 did not improve ADAS-Cog scores or any secondary end point; however, donepezil significantly improved both cognition and functional end points. Overall incidence of adverse events was similar among treatment groups.
CONCLUSION:
ABT-384, when tested at doses associated with complete brain HSD-1 inhibition, did not produce symptomatic improvement in AD.
- Forums
- ASX - By Stock
- ACW
- 2014 trial of similar drug
2014 trial of similar drug
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
2.7¢ |
Change
0.002(8.00%) |
Mkt cap ! $73.21M |
Open | High | Low | Value | Volume |
2.6¢ | 2.8¢ | 2.5¢ | $131.3K | 4.903M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 4494717 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 2125342 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 4494717 | 0.026 |
33 | 6783667 | 0.025 |
12 | 3194302 | 0.024 |
9 | 1048348 | 0.023 |
5 | 863300 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 2125342 | 8 |
0.028 | 1793335 | 12 |
0.029 | 1815153 | 16 |
0.030 | 3299517 | 11 |
0.031 | 2184412 | 9 |
Last trade - 11.50am 15/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online